ORIGINAL ARTICLES
Probenecid Hypersensitivity in AIDS: a Case Report

https://doi.org/10.1016/S1081-1206(10)62994-8Get rights and content

Background

Cidofovir plus probenecid is a new therapeutic alternative for refractory cytomegalovirus and acyclovir-resistant herpes infections in AIDS patients. Probenecid is used in conjunction with the antiherpetic medication (cidofovir) in order to reduce the incidence of nephrotoxicity by cidofovir.

Objective

To present therapeutic alternatives for successful administration of probenecid to AIDS patients who develop a hypersensitivity reaction to the medication.

Methods and results

We describe a patient with AIDS who was being treated with the cidofovir/probenecid combination for a perianal acyclovir-resistant herpetic infection. The patient subsequently developed a cutaneous hypersensitivity reaction to probenecid alone. A pretreatment regimen consisting of prednisone, H1 and H2 blockers was administered before the dosing of probenecid in order for the patient to continue with the antiviral therapy.

Conclusion

Cutaneous hypersensitivity reactions to probenecid may be seen more frequently with the increasing use of cidofovir in AIDS patients. Our pretreatment protocol is one therapeutic alternative to be considered in order to continue with probenecid.

REFERENCES (9)

There are more references available in the full text version of this article.

Cited by (12)

  • Optimization of the THP-1 activation assay to detect pharmaceuticals with potential to cause immune mediated drug reactions

    2015, Toxicology in Vitro
    Citation Excerpt :

    Clonidine, ofloxacin, procainamide, streptozotocin, sulfamethoxazole have been associated with a relatively high incidence of immune-mediated hypersensitivity reactions (Weaver et al., 2005). Methyl salicylate in topical analgesic preparations as well al probenecid has been reported to cause irritant or allergic contact dermatitis and anaphylactic reactions (Chan, 1996; Myers et al., 1998). The proposed screening assay has the potential to identify adverse effects on the immune system (i.e. immune-mediated hypersensitivity reactions, including both immediate and nonimmediate HDRs), and can be easily incorporated into drug development prior to phase III clinical trials.

  • Meyler’s Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, Sixteenth Edition

    2015, Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions
  • Probenecid: An emerging tool for neuroprotection

    2013, CNS and Neurological Disorders - Drug Targets
View all citing articles on Scopus

The opinions or assertions contained herein are the private views of the authors and are are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.

View full text